Position in LYEL
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$445,472
+$187,079 QoQ
Shares Held
22,207
-24.0% QoQ
Ownership
0.095%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Walleye Capital LLC holds $278,334,962 across 104 Biotechnology names. LYEL ranks #72 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMRN |
Biomarin Pharmaceutical Inc
|
364,246 | $20,576,256 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
228,593 | $16,975,316 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
87,365 | $16,516,353 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,752 | $13,731,998 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
153,585 | $12,888,853 | |
| 6 | CELC |
Celcuity Inc.
|
105,688 | $12,063,228 | |
| 7 | INSM |
INSMED Inc
|
71,819 | $11,743,842 | |
| 8 | SNDX |
Syndax Pharmaceuticals Inc
|
384,973 | $8,992,969 |
All Filings in LYEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $445,472 | 22,207 | Shares | Sole | 2026-05-13 | |
| 2025-06-30 | $258,393 | 29,230 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||